Tag: treatment

VANCOUVER, British Columbia, June 20, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) announces that it has granted 799,920 restricted share units (“RSUs”) and 162,480 stock options (“Options”) to officers, directors, consultants and employees of the Company.

BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) today announced that it has postponed its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), which was scheduled to be held on June 25, 2025, in light of the previously announced acquisition (the “Acquisition”) by BioMarin Pharmaceutical Inc. (“BioMarin”).

DUBAI, United Arab Emirates, June 20, 2025 (GLOBE NEWSWIRE) -- As the world confronts an escalating climate emergency marked by rising global temperatures, deforestation, water scarcity, and deteriorating air quality, the need for inclusive and scalable solutions has never been greater. BigWater Protocol introduces a new initiative that leverages blockchain technology, artificial intelligence, and community engagement to support environmental sustainability on a global scale.

SHENZHEN, China, June 20, 2025 (GLOBE NEWSWIRE) -- CDT Environmental Technology Investment Holdings Limited (NASDAQ:CDTG) (“CDT” or the “Company”), a leading provider of waste treatment systems and services throughout China, today announced that it received a notification letter, dated June 18, 2025 (the “Notification Letter”), from the Listing Qualifications Department of The Nasdaq Stock Market Inc. (“Nasdaq”) indicating that the Company is no longer in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) as the Company’s closing bid price per ordinary share, par value US$0.0025 per share, was below US$1.00 for a period of 30 consecutive business days. The Notification Letter does not result in the immediate delisting of the Company’s securities.

NOVATO, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 48,731 restricted stock units of the company’s common stock to 26 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of June 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

Conference call and webcast on Monday, June 23, 2025 at 8:00 am EDT

Virtual webinar on June 23, 2025 at 8:00 am ET

Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation

GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it entered into a securities purchase agreement with an accredited investor for aggregate gross proceeds of $4.25 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for potential acquisitions, marketing and other general corporate purposes.